. "NS9614" . . . "Influence of biocompatible coated heart lung machine tubing set on fibrinogen function, assessed by the TEG Functional Fibrinogen"@en . "2013-10-31+01:00"^^ . " functional fibrinogen" . "Stanoven\u00ED vlivu biokompatibin\u00ED \u00FApravy vnit\u0159n\u00EDho povrchu syst\u00E9mu pro mimot\u011Bln\u00ED ob\u011Bh na funkci fibrinogenu metodou TEG Funk\u010Dn\u00ED Fibrinogen" . "http://www.isvav.cz/projectDetail.do?rowId=NS9614"^^ . "TEG" . " extracorporeal circulation" . " blood loss" . "Biocompatible surface of extracorporeal circulation decreases in the early postoperative period of functional decline in the proportion of platelets."@en . . . . . . "0"^^ . "2"^^ . . . "2"^^ . "1"^^ . "The goal of our project is to compare the impact of a biocompatible coated extracorporeal system with the non coated system on functional competency of fibrinogen and platellets. Patients will be randomly assigned to a group with a biocompatible coated system for extracorporeal circulation tubing set ( group C), or a group without this coating (group N). Each group will comprise of 75 patients. Despite standard preoperative tests (incl thrombocytes, INR, aPTT and DD), fibrinogen level will be obtained by the standard Von Clauss method and coagulation examination TEG and TEG Funtional fibrinogen (Haemoscope Corp. IL, USA) will be performed. Ratio of functional to total fibrinogen will be assessed. Measurements will be repeated 2 hours and 2 days after the operation. At the end, fibrinogen protection rate against functional damage, caused by both systems, will be evaluated."@en . " cardiac surgery" . "Biokompatibiln\u00ED povrch syst\u00E9mu mimot\u011Bln\u00EDho ob\u011Bhu sni\u017Euje v \u010Dasn\u00E9m poopera\u010Dn\u00EDm obdob\u00ED pokles funk\u010Dn\u00EDho pod\u00EDlu trombocyt\u016F."@cs . . "0"^^ . "2011-12-31+01:00"^^ . . . "TEG; functional fibrinogen; extracorporeal circulation; biocompatible surface; cardiac surgery; blood loss; haemotherapy"@en . "2009-01-01+01:00"^^ . . . . . "C\u00EDlem projektu je srovn\u00E1n\u00ED dopadu pou\u017Eit\u00ED biokompatibiln\u011B pota\u017Een\u00E9ho povrchu mimot\u011Bln\u00EDho ob\u011Bhu se syst\u00E9mem nepota\u017Een\u00FDm na funk\u010Dn\u00ED kompetenci fibrinogenu a trombocyt\u016F . Pacienti budou randomizov\u00E1ni do skupiny s biokompatibiln\u011B pota\u017Een\u00FDm syst\u00E9mem pro mimot\u011Bln\u00ED ob\u011Bh ( skupina C) a syst\u00E9mem bez tohoto pota\u017Een\u00ED (N). V ka\u017Ed\u00E9 skupin\u011B pl\u00E1nujeme 75 pacient\u016F. Pacient\u016Fm obou skupin budou krom\u011B b\u011B\u017En\u00FDch p\u0159edopera\u010Dn\u00EDch odb\u011Br\u016F vy\u0161et\u0159ena standartn\u00ED laboratorn\u00ED metodou dle Von Clausse hladina fibrinogenu a provedena vy\u0161et\u0159en\u00ED koagulace TEG i TEG Funk\u010Dn\u00ED Fibrinogen (Haemoscope Corporation, IL, USA). Stanov\u00EDme pom\u011Br funk\u010Dn\u00EDho fibrinogenu na celkov\u00E9m fibrinogenu. Tyto odb\u011Bry budou opakov\u00E1ny 2 hodiny po operaci a 2. poopera\u010Dn\u00ED den. Z\u00E1v\u011Brem srovn\u00E1me m\u00EDru protekce fibrinogenu i trombocyt\u016F v obou skupin\u00E1ch." . . " biocompatible surface" .